西妥昔单抗联合FOLFIRI方案对结肠癌患者炎性因子、免疫功能及预后的影响  

Effects of cetuximab combined with FOLFIRI regimen on inflammatory factors,immune function,and prognosis in patients with colon cancer

作　　者：王高波 杨洋[1] 王佳 孙兴伟 WANG Gaobo;YANG Yang;WANG Jia;SUN Xingwei(Department of Colorectal and Anal Surgery,Baoji People’s Hospital,Baoji 721000,Shaanxi,China;Department of Colorectal and Anal Surgery,Xi’an Hospital of Traditional Chinese Medicine,Xi’an 710021,Shaanxi,China)

机构地区：[1]宝鸡市人民医院结直肠肛门外科,陕西宝鸡721000 [2]西安市中医医院结直肠肛门外科,西安710021

出　　处：《癌症进展》2023年第19期2128-2131,共4页Oncology Progress

基　　金：陕西省重点研发计划项目(2022SF-369)。

摘　　要：目的探讨西妥昔单抗联合伊立替康+亚叶酸钙+5-氟尿嘧啶(FOLFIRI)方案对结肠癌患者炎性因子、免疫功能及预后的影响。方法根据化疗方案的不同将84例结肠癌患者分为对照组(n=41)和观察组(n=43),对照组患者给予FOLFIRI方案化疗,观察组患者给予西妥昔单抗联合FOLFIRI方案治疗。比较两组患者炎性因子[白细胞介素(IL)-4、IL-8、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)]水平、外周血T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平、不良反应及生存率。结果治疗后,两组患者IL-4、IL-8、CRP、TNF-α水平均低于本组治疗前,观察组患者IL-4、IL-8、CRP、TNF-α水平均低于对照组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,CD8^(+)水平均低于本组治疗前,观察组患者CD3^(+)、CD4^(+)水平和CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异均有统计学意义(P﹤0.05)。对照组患者的不良反应总发生率为63.41%,与观察组患者的69.77%比较,差异无统计学意义(P﹥0.05)。观察组患者1、2年生存率均高于对照组,差异均有统计学意义(P﹤0.05)。结论西妥昔单抗联合FOLFIRI方案能够改善Kirsten鼠类肉瘤病毒癌基因同源物(KRAS)野生型结肠癌患者的炎性因子及T淋巴细胞亚群水平,提高患者的生存率,安全性较高。Objective To investigate the effects of cetuximab combined with the irinotecan+calcium folinate+5-fluorouracil(FOLFIRI)regimen on inflammatory factors,immune function,and prognosis in patients with colon cancer.Method A total of 84 patients with colon cancer were divided into control group(n=41)and observation group(n=43)according to different chemotherapy regimens.Patients in the control group were given FOLFIRI regimen chemotherapy,and patients in the observation group were given cetuximab combined with FOLFIRI regimen treatment.The levels of inflammatory factors[interleukin(IL)-4,IL-8,C-reactive protein(CRP),tumor necrosis factor-α(TNF-α)],peripheral blood T lymphocyte subsets(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+)),adverse events,and survival were compared between the two groups.Result After treatment,the levels of IL-4,IL-8,CRP,and TNF-αin both groups were lower than those before the treatment,and the levels of these inflammatory factors in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the two groups were higher than those before the treatment,and the CD8^(+)levels were lower than those before the treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in the observation group were higher than those of the control group,while the level of CD8^(+)was lower than that of the control group,and the differences were statistically significant(P<0.05).The total incidence rate of adverse events in the control group was 63.41%,which was not statistically significant from 69.77%in the observation group(P>0.05).The 1-and 2-year survival rates in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).Conclusion Cetuximab combined with FOLFIRI regimen could improve the levels of inflammatory factors and T lymphocyte subsets in patients with Kirsten rat sarcoma viral oncogene homolog(KRAS)wild-type colon

关 键 词：结肠癌 西妥昔单抗 FOLFIRI方案 预后 

分 类 号：R735.35[医药卫生—肿瘤]